Entries |
Document | Title | Date |
20080207636 | Compounds Effecting Glucokinase - The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R | 08-28-2008 |
20080214565 | Oxazolidinone Derivatives as Antimicrobials - The present invention relates to certain substituted phenyl oxazolidinones of formula I and H and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms as | 09-04-2008 |
20080214566 | Amorphous ziprasidone mesylate - Provided is amorphous form of ziprasidone mesylate and process for its preparation. Also provided is a process for preparing ziprasidone mesylate dihydrate needle crystals. | 09-04-2008 |
20080221122 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE - Compounds represented by the following structure (II) are disclosed: | 09-11-2008 |
20080234288 | Hcv Inhibiting Sulfonamides - The present invention concerns sulfonamide derivatives having the general formula | 09-25-2008 |
20080300259 | Multimediator 5-Ht6 Receptor Antagonists, and Uses Related Thereto - The invention provides a class of 5HT6—D3/DAT compounds, packaged pharmaceuticals comprising such compounds, and their uses in treating, or manufacturing medicaments for treating disease conditions, including a movement disorder, anxiety, depression or psychotic disorder (e.g. Bipolar Disorder, Bipolar Depression or Unipolar Depression, etc.). Related business methods such as marketing the compounds to healthcare providers are also provided. | 12-04-2008 |
20080312254 | Process for the Preparation of Ziprasidone - The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia. | 12-18-2008 |
20090018140 | THIAZOLES AND OXAZOLES USEFUL AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 01-15-2009 |
20090023747 | Cysteine Protease Inhibitors - A compound of the formula (II) wherein one of R | 01-22-2009 |
20090023748 | Cysteine Protease Inhibitors - Compounds of the formula II: | 01-22-2009 |
20090036467 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS - A new class of alkylsulfonyl-substituted thiazolide compounds is described. These compounds show strong activity against hepatitis virus. | 02-05-2009 |
20090054457 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I: | 02-26-2009 |
20090088442 | PROPHYLACTIC/THERAPEUTIC AGENT FOR ABNORMALITIES OF SUGAR/LIPID METABOLISM - The present invention provides a pharmaceutical agent for the treatment and/or prophylaxis of abnormal blood glucose and lipid metabolism associated with eating, for which a sufficient treatment method or a therapeutic drug has not been found. | 04-02-2009 |
20090093497 | Diacylglycerol Acyltransferase Inhibitors - Provided herein are compounds of the formula (I): | 04-09-2009 |
20090099200 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase - Azacyclohexane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis. | 04-16-2009 |
20090099201 | Diacylglycerol Acyltransferase Inhibitors - Provided herein are compounds of the formula (I): | 04-16-2009 |
20090105273 | Diacylglycerol Acyltransferase Inhibitors - Provided herein are compounds of the formula (I): | 04-23-2009 |
20090149471 | Monocyclic Heterocyclic Compounds - This invention relates to compounds of the general formula: | 06-11-2009 |
20090163513 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES - The present invention relates to a novel process for the preparation of high purity ziprasidone and pharmaceutically acceptable acid addition salts of ziprasidone; and solvates and hydrates thereof using novel intermediates and a purification method for ziprasidone and pharmaceutically acceptable acid addition salts of ziprasidone; and solvates and hydrates thereof. | 06-25-2009 |
20090186905 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE - The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R | 07-23-2009 |
20090197895 | OXAZOLE-PYRROLE-PIPERAZINE ALPHA-HELIX MIMETIC - Amphiphilic α-helix mimetics are provided. These compounds are constructed using an oxazole-pyrrole-piperazine (OPP) scaffold. The amphiphilic α-helix mimetics are also employable for making libraries and for treating diseases or conditions effected by the inhibition or disruption of interactions with the alpha helix of a protein. | 08-06-2009 |
20090203712 | Urea Derivative - Disclosed is a novel compound having an NPY Y5 receptor antagonistic activity. | 08-13-2009 |
20090215796 | Compositions, Kits and Methods for a Titration Schedule for Pardoprunox Compounds - The present invention is directed to compositions, kits, and methods for a titration schedule to facilitate the treatment of a central nervous system condition or disorder by administering a plurality of dosage units of a composition comprising a compound 7-(4-methyl)-1-piperazinyl-2(3H)-benzoxazolone (INN pardoprunox). | 08-27-2009 |
20090221604 | Thiazole Compounds and Their Use as PGD2 Antagonists - A compound for use as a PGD2 antagonist is of structural formula [1] in which: A represents a fully saturated or partially unsaturated monocyclic 5-7 membered ring containing one or two nitrogen atoms; B represents a direct bond, an optionally substituted methylene group, an optionally substituted nitrogen atom, oxygen, or S(O) | 09-03-2009 |
20090247545 | SUBSTITUTED OXAZOLIDINONE DERIVATIVES - The present invention provides substituted oxazolidinone derivatives, which can be used as antimicrobial agents. Compounds disclosed can be used for the treatment or prevention of a condition caused by or contributed to by bacteria, such as, inter alia, multiply-resistant | 10-01-2009 |
20090286805 | Solubiliazation preparation - A solution-type preparation of lurasidone comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) as an active ingredient and containing at least one substance selected from benzyl alcohol, N,N-dimethylacetamide, lactic acid and propylene glycol. | 11-19-2009 |
20100029681 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS - Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of heterocyclic compounds are disclosed of the general formula (1) where X | 02-04-2010 |
20100029682 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME - The present invention relates to novel chromene or thiochromene carboxamide derivatives, the preparation of same, pharmaceutical compositions of same and the use of same as dopamine D3 ligands as a medicament for central nervous system disorders. | 02-04-2010 |
20100075983 | D3 AND 5-HT2A RECEPTOR MODULATORS - The present invention provides compounds of the general formula (I) | 03-25-2010 |
20100130508 | PHARMACEUTICAL COMPOSITION COMPRISING 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE DERIVATIVES - A pharmaceutical composition according to the present invention comprises: (I) at least one member selected from the group consisting of oxazole compounds, optically active isomers thereof, and salts thereof, the oxazole compounds being represented by general formula (1): wherein R | 05-27-2010 |
20100197703 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES - This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients. | 08-05-2010 |
20100216810 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. | 08-26-2010 |
20100234395 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF - Discloses is a pharmaceutical agent comprising an ureide derivative represented by the formula: or a pharmaceutically acceptable salt thereof as an active ingredient. The ureide derivative or the pharmaceutically acceptable salt thereof is useful for the relief of a pain or the treatment or prevention of neurogenic pain. | 09-16-2010 |
20100292248 | COMBINATION PREPARATIONS COMPRISING SLV308 AND A DOPAMINE AGONIST - A composition containing SLV308 or its N-oxide, or at least one pharmacologically acceptable salt thereof: | 11-18-2010 |
20100298340 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies - This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia. | 11-25-2010 |
20100305139 | METHOD OF TREATING ABNORMAL LIPID METABOLISM - The present invention provides a pharmaceutical agent for the treatment and/or prophylaxis of abnormal blood glucose and lipid metabolism associated with eating, for which a sufficient treatment method or a therapeutic drug has not been found. | 12-02-2010 |
20110039862 | Protease Inhibitors - Compounds of the formula II: | 02-17-2011 |
20110046153 | Medicaments - A compound of formal (I) is described: wherein R | 02-24-2011 |
20110053955 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS - Heterocyclic compounds which are inhibitors of Mitrogen-Activated Protein Kinase-Activated Protein Kinase-2 (MAPKAP-K2) as described, in addition to their use in the treatment of cytokine mediated diseases. | 03-03-2011 |
20110086862 | POLYMORPHS OF PARDOPRUNOX - This invention relates to a process for the preparation of 7-(4-methyl-1-piperazinyl)benzoxazol-2(3H)-one hydrochloride, a partial dopamine-D | 04-14-2011 |
20110092517 | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases - Provided herein are methods for treatment, prevention, or amelioration of one or more symptoms of a disease or condition related to disorders of insulin and/or glucose metabolism, inflammatory conditions, mitochondrial disease, muscle disorders, or pulmonary disorders, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist. In one embodiment, the disease or condition is selected from myopathy, inflammatory vascular diseases, Parkinson's and Alzheimer's diseases, systemic inflammatory disorders, renal ischemia, inflammatory rheumatic disorders, and inflammatory diseases of the lung. In another embodiment, methods for increasing oxidative muscle fibers, reducing mitochondria disease, decreasing insulin resistance, decreasing plasma glucose, or decreasing weight, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist, are provided. | 04-21-2011 |
20110105523 | BIFEPRUNOX DERIVATIVES - The present invention relates to bifeprunox derivatives of formula (I) wherein R1 is one substituent chosen from 3-OH, 4-OH, 3-OSO3H and 4-OSO3H; R2 is H; or an N-oxide or a pharmaceutically acceptable salt, or a solvate or hydrate of any of the foregoing. The compounds of the invention may be used in the treatment or alleviation of dopamine D | 05-05-2011 |
20110136822 | CERTAIN CRYSTALLINE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE THEREOF - At least one crystalline hydrate of (S)—[N-3-(3′-fluoro-4′-(4″-phenyl piperazinyl))phenyl-2-oxo-5-oxazolidinyl]methyl acetamide, such as those with the following formula: | 06-09-2011 |
20110144123 | Thiazoles and Oxazoles Useful as Modulators of ATP-Binding Cassette Transporters - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 06-16-2011 |
20110152287 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 - The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1. | 06-23-2011 |
20110172245 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a heterocyclic compound showing strong Raf inhibitory activity. A compound represented by the formula | 07-14-2011 |
20110251214 | MONOHYDRATE OF PARDOPRUNOX - This invention relates to a process for the preparation of 7-(4-methyl-1-piperazinyl)benzoxazol-2(3H)-one hydrochloride, a partial dopamine-D | 10-13-2011 |
20110294822 | Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof - The invention relates to a substituted phenylpiperazine aryl alkanol derivative represented by the following general formula and its salt and hydrate, | 12-01-2011 |
20110319423 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME - The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction. | 12-29-2011 |
20120015959 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS - Compounds of the formula (I), in which Het, R, X, Y, R | 01-19-2012 |
20120028990 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE - A 3-aryl or heteroaryl-substituted indole derivative which is effective as a preventive or remedy for various diseases is provided. [Means for Resolution] A compound represented by a formula (I) or a pharmaceutically acceptable salt thereof is provided. In the formula, R1 represents a hydrogen atom, C1-6 alkyl et al; R2 represents a hydrogen atom, C1-6 alkyl et al; Z represents aryl or heteroaryl (with the proviso that imidazolyl is excluded); and W represents a group represented by the formula (w-1) or (w-2). In the formula, R3 represents C1-6 alkyl et al; Yl and Y2 both represent a hydrogen atom or Y1 and Y2 together form —CH2-CH2-; Q represents CH or N; Ar represents phenyl, furyl et al; R4 and R5 each independently represent a hydrogen atom or C1-6 alkyl or R4 and R5 together with the nitrogen atom form pyrrolidine et al. | 02-02-2012 |
20120129872 | FUSED HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION - This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables A, Q, J, R | 05-24-2012 |
20120172374 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME - Compounds represented by the formula (I) or pharmaceutically acceptable salts thereof: | 07-05-2012 |
20120202827 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS - Sulfoxide derivatives of the formula Ia to Im as described, and pharmaceutically usable salts, solvates, enantiomers, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the treatment of tumours. | 08-09-2012 |
20120220602 | CYSTEINE PROTEASE INHIBITORS - Compounds of the formula II: | 08-30-2012 |
20120264763 | Indoline Anti-Cancer Agents - Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided. | 10-18-2012 |
20120289519 | PROTEASE INHIBITORS - Compounds of the formula II: | 11-15-2012 |
20130005738 | Monocyclic Heteroaryl Compounds - This invention relates to compounds of the general formula: | 01-03-2013 |
20130023542 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE - The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis. | 01-24-2013 |
20130030007 | Obesity Small Molecules - The present invention relates to new therapies to treat obesity and related diseases, as well as for reducing triglyceride levels and body weight. | 01-31-2013 |
20130085147 | Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein. | 04-04-2013 |
20130131080 | Novel Compounds - The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): | 05-23-2013 |
20130165450 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors - This invention relates to certain thiazole carboxamide derivatives of Formula (I) as inhibitors of 3-phosphoinositide-dependent protein kinase (PDK-1). The compounds can be useful in inhibiting the proliferation of cancer cells, and other aberrant conditions where the PDK-1 signaling pathway is overstimulated. | 06-27-2013 |
20130172364 | PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE - Disclosed are novel derivatives of propargyl-trifluoromethoxy-amino-benzothiazole which are effective in treating neurologic disorders, including Parkinson's disease and multiple sclerosis. | 07-04-2013 |
20130203772 | Polymorphs and Salts - The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity. | 08-08-2013 |
20130231349 | PROTEASE INHIBITORS - Compounds of the formula II: | 09-05-2013 |
20130252969 | Compounds - A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 09-26-2013 |
20130310396 | THIAZOLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE - This invention provides deuterated thiazolidine derivatives and compositions comprising these compounds, which are useful agents for the treatment of hyperglycemia diseases or disorders, in particular diabetes mellitus. The disclosure also provides a method of treating hyperglycemia diseases or disorders, in particular diabetes mellitus, using these deuterated thiazolidine derivatives. | 11-21-2013 |
20140073648 | METHODS FOR TREATING IMMUNOLOGIC DISEASE USING AMINOTHIAZOLE-BASED INHIBITOR OF MYD88 - A method of treating an immunologic disease. The method includes administering an aminothiazole-based inhibitor of myeloid differentiation protein 88 (MyD88) to a patient in need thereof. The inhibitor of MyD88 acts as an immunomodulator for treatment of the immunologic disease including but not limited to rejections after organ transplantation, chronic inflammatory diseases, autoimmune diseases, ischemia-reperfusion injuries, and endotoxemia and sepsis. | 03-13-2014 |
20140080840 | Thiazolamine Derivative and Use Thereof as Anti-Picornaviral Infection Medicament - Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application thereof in the prevention and/or treatment of viral diseases induced by picornavirus. Also disclosed is a pharmaceutical composition containing the compound. | 03-20-2014 |
20140121217 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I): | 05-01-2014 |
20140243351 | DRUG FOR THE TREATMENT OF ALLERGIC RHINITIS COMPRISING PGD2 ANTAGONIST AND HISTAMINE ANTAGONIST - A medicament for treating allergic rhinitis, characterized in that (A) a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, is combined with (B) at least one compound selected from the group consisting of cetirizine, fexofenadine, and loratadine, or a pharmaceutically acceptable salt thereof. Since the effects of the medicament for treating allergic rhinitis of the present invention surpass the sum of the effects of single dose of each of the agents against the allergic rhinitis, the medicament is useful as a medicament for treating allergic rhinitis having potent effects. | 08-28-2014 |
20140315919 | HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS - A compound useful for treating subjects in need of therapy involving sigma receptors or for alleviation of affects resulting from drug abuse having the general formula I | 10-23-2014 |
20140329831 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME - The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction. | 11-06-2014 |
20150018367 | AURORA AND FLT3 KINASES MODULATORS - The invention provides a compound having the formula (1): | 01-15-2015 |
20150111897 | TYROSINASE INHIBITORS - The compositions and methods of described herein comprise novel ingredients effective to reduce unwanted pigmentation, such as skin discoloration, freckles, age spots, liver spots, sun damage, tans, pigmented acne marks, scars, pigmented birthmarks, hyperpigmentation, post-inflammatory hyperpigmentation, post-injury hyperpigmentation, melasma, cholasma, after-burn scar, nail stain, yellowing of skin, dark circles under eyes, and the like. The composition may include additional ingredients accordingly for a colored cosmetic, moisturizer, cleanser, toner, and the like. | 04-23-2015 |
20150291539 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS - Pharmaceutical compositions of the invention comprise disubstituted oxazolidin-2-ones derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 2b activity. | 10-15-2015 |
20150353530 | NOVEL FUNCTIONALIZED 4-(PHENOXYMETHYL(-1,3-DIOXOLANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE - Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of cortisol that include metabolic syndrome, and any involving the overproduction of cortisol. | 12-10-2015 |
20150361092 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 - The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them. | 12-17-2015 |
20160002187 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 01-07-2016 |
20160045494 | METHODS FOR DETERMINING THE RISK OF CARDIOVASCULAR DISEASE IN A SUBJECT HAVING A CHRONIC VIRAL INFECTION - A method for determining the risk of cardiovascular disease in a subject having a chronic viral infection includes determining a level of ectonucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) in the subject and comparing the determined level of ENPP2 to a control level, wherein an increased level of ENPP2 is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection. | 02-18-2016 |
20160136283 | SOLUTION FOR SPRAY DRYING COMPRISING HYPROMELLOSE ACETATE SUCCINATE AND METHOD FOR PRODUCING SOLID DISPERSION - There are provided a solution for spray drying having a high transmittance and markedly reduced generation of undissolved matter; and a method for producing a solid dispersion by using the solution for spray drying so that clogging with the undissolved matter is reduced and dissolution is improved. More specifically, there is provided a solution for spray drying comprising hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more, a solvent, and a drug. There is also provided a method for producing a solid dispersion comprising the step of removing the solvent from the spray drying solution. | 05-19-2016 |
20160193209 | NAMPT INHIBITORS | 07-07-2016 |
20170231226 | FUSED 11-MEMBERED COMPOUNDS AND AGRICULTURAL/HORTICULTURAL FUNGICIDES CONTAINING THEM | 08-17-2017 |